acitretin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
retinol derivatives 78 55079-83-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • acitretin
  • acitretinoin
  • etretin
  • neotigason
  • soriatane
  • isoacitretin
  • isoetretin
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
  • Molecular weight: 326.44
  • Formula: C21H26O3
  • CLOGP: 6.07
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.83
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
35 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.83 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 59 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 28, 1996 FDA STIEFEL LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 934.57 22.43 393 9938 86564 63392127
Skin haemorrhage 260.36 22.43 87 10244 10007 63468684
Skin exfoliation 205.86 22.43 112 10219 42990 63435701
Neurologic neglect syndrome 191.64 22.43 51 10280 2670 63476021
Carotid artery thrombosis 190.30 22.43 51 10280 2743 63475948
Personality disorder 153.44 22.43 51 10280 5760 63472931
Respiratory tract congestion 152.76 22.43 69 10262 17763 63460928
Adjustment disorder 147.69 22.43 43 10288 3135 63475556
Sinus congestion 139.18 22.43 65 10266 18058 63460633
Sneezing 138.85 22.43 65 10266 18153 63460538
Hemiplegia 129.90 22.43 51 10280 9272 63469419
Sensory loss 128.71 22.43 52 10279 10186 63468505
Affect lability 124.42 22.43 52 10279 11099 63467592
Motor dysfunction 122.82 22.43 51 10280 10710 63467981
Sinus disorder 120.48 22.43 65 10266 24488 63454203
Coordination abnormal 110.72 22.43 51 10280 13722 63464969
Psoriatic arthropathy 103.77 22.43 99 10232 91421 63387270
Rhinorrhoea 96.13 22.43 82 10249 65495 63413196
Muscle spasticity 91.30 22.43 52 10279 21742 63456949
Hemiparesis 88.10 22.43 52 10279 23230 63455461
Eating disorder 78.65 22.43 45 10286 18971 63459720
Aphasia 73.82 22.43 53 10278 32947 63445744
Cystitis 71.01 22.43 64 10267 54927 63423764
Arterial occlusive disease 63.83 22.43 27 10304 5931 63472760
Skin lesion 63.41 22.43 47 10284 30674 63448017
Gangrene 63.12 22.43 27 10304 6096 63472595
Influenza like illness 62.24 22.43 65 10266 66759 63411932
Influenza 61.65 22.43 82 10249 108640 63370051
Drug ineffective 61.51 22.43 332 9999 1044433 62434258
Skin plaque 61.26 22.43 29 10302 8291 63470400
Cutaneous T-cell lymphoma 61.15 22.43 18 10313 1362 63477329
Dysarthria 59.70 22.43 52 10279 42659 63436032
Oral lichen planus 58.63 22.43 15 10316 671 63478020
Infected dermal cyst 53.93 22.43 13 10318 454 63478237
Angina pectoris 53.24 22.43 42 10289 30036 63448655
Rash pustular 52.44 22.43 25 10306 7257 63471434
Dysphagia 52.04 22.43 68 10263 88517 63390174
Erythema 51.53 22.43 98 10233 175653 63303038
Rhesus antigen positive 51.31 22.43 10 10321 124 63478567
Pruritus 50.60 22.43 151 10180 361302 63117389
Pain of skin 44.04 22.43 26 10305 11608 63467083
Lichen planus 40.51 22.43 15 10316 2323 63476368
Squamous cell carcinoma 39.95 22.43 22 10309 8610 63470081
Erythrodermic psoriasis 39.57 22.43 12 10319 1006 63477685
Guttate psoriasis 39.05 22.43 10 10321 449 63478242
Dry skin 38.69 22.43 47 10284 56840 63421851
Oesophageal stenosis 35.65 22.43 15 10316 3251 63475440
Weaning failure 35.19 22.43 9 10322 402 63478289
Tongue ulceration 34.38 22.43 15 10316 3551 63475140
Skin fissures 34.31 22.43 22 10309 11366 63467325
Wrong technique in device usage process 34.25 22.43 15 10316 3583 63475108
Rebound psoriasis 34.20 22.43 7 10324 113 63478578
Cataract 33.80 22.43 44 10287 57009 63421682
Blood albumin increased 31.66 22.43 10 10321 959 63477732
Blood immunoglobulin M decreased 31.47 22.43 10 10321 978 63477713
Oesophageal ulcer 31.07 22.43 15 10316 4475 63474216
Arthritis 30.73 22.43 62 10269 115859 63362832
Dermatitis exfoliative generalised 30.28 22.43 14 10317 3793 63474898
Cerebrovascular accident 30.10 22.43 59 10272 107965 63370726
Toxicity to various agents 29.51 22.43 3 10328 247247 63231444
Burning sensation 29.22 22.43 40 10291 54367 63424324
Nasopharyngitis 28.91 22.43 99 10232 254158 63224533
Type IIb hyperlipidaemia 28.90 22.43 5 10326 30 63478661
Immunoglobulins decreased 28.84 22.43 10 10321 1282 63477409
Actinic keratosis 28.55 22.43 12 10319 2592 63476099
Diffuse alopecia 28.06 22.43 9 10322 907 63477784
Sunburn 27.76 22.43 12 10319 2776 63475915
Pustular psoriasis 27.68 22.43 14 10317 4612 63474079
Onychalgia 27.54 22.43 9 10322 962 63477729
Injection site bruising 27.48 22.43 34 10297 41876 63436815
Swelling 26.82 22.43 6 10325 275372 63203319
Infusion related reaction 26.81 22.43 4 10327 245517 63233174
Inflammatory bowel disease 26.67 22.43 13 10318 3960 63474731
Sticky skin 26.18 22.43 4 10327 9 63478682
Increased bronchial secretion 25.79 22.43 10 10321 1756 63476935
Face oedema 25.04 22.43 23 10308 20189 63458502
Skin infection 24.52 22.43 20 10311 14982 63463709
Tanning 24.18 22.43 5 10326 85 63478606
Palmoplantar pustulosis 24.09 22.43 7 10324 506 63478185
Skin atrophy 24.08 22.43 13 10318 4893 63473798
Intertrigo 22.83 22.43 7 10324 609 63478082
Blood immunoglobulin G decreased 22.59 22.43 10 10321 2448 63476243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 733.62 21.90 283 7075 38529 34911044
Drug ineffective 232.80 21.90 372 6986 456379 34493194
Vein rupture 179.14 21.90 41 7317 873 34948700
Skin plaque 176.31 21.90 57 7301 4557 34945016
Psoriatic arthropathy 126.32 21.90 68 7290 19730 34929843
Skin injury 114.72 21.90 35 7323 2310 34947263
Venous injury 105.87 21.90 22 7336 292 34949281
Injection site haemorrhage 96.05 21.90 45 7313 9723 34939850
Hepatic fibrosis 95.17 21.90 36 7322 4571 34945002
Anti-cyclic citrullinated peptide antibody positive 87.99 21.90 27 7331 1816 34947757
Erythrodermic psoriasis 87.43 21.90 23 7335 884 34948689
Joint ankylosis 83.49 21.90 25 7333 1547 34948026
Treatment failure 83.47 21.90 73 7285 46624 34902949
Bone cyst 83.06 21.90 25 7333 1575 34947998
Injection site papule 81.54 21.90 18 7340 323 34949250
Therapeutic product effect incomplete 78.50 21.90 73 7285 50468 34899105
Dermatitis exfoliative generalised 76.68 21.90 29 7329 3678 34945895
Drug intolerance 75.58 21.90 77 7281 59493 34890080
Hepatic cirrhosis 74.40 21.90 46 7312 17268 34932305
Pruritus 71.72 21.90 116 7242 141865 34807708
Cutaneous T-cell lymphoma 71.17 21.90 22 7336 1516 34948057
Injection site swelling 69.06 21.90 38 7320 11489 34938084
Pain of skin 69.01 21.90 31 7327 6078 34943495
Osteolysis 66.46 21.90 25 7333 3123 34946450
Red blood cell sedimentation rate abnormal 63.28 21.90 25 7333 3564 34946009
Hand deformity 62.38 21.90 25 7333 3700 34945873
Bone erosion 60.56 21.90 25 7333 3990 34945583
Squamous cell carcinoma 58.40 21.90 34 7324 11441 34938132
Inappropriate schedule of product administration 57.24 21.90 68 7290 62228 34887345
Alanine aminotransferase abnormal 56.83 21.90 25 7333 4663 34944910
Skin erosion 53.05 21.90 19 7339 2066 34947507
Gastrointestinal infection 51.75 21.90 25 7333 5773 34943800
Granuloma annulare 51.74 21.90 11 7347 164 34949409
Hypercholesterolaemia 47.35 21.90 27 7331 8735 34940838
Phototherapy 46.87 21.90 8 7350 32 34949541
Keratoacanthoma 46.35 21.90 13 7345 637 34948936
Squamous cell carcinoma of skin 44.43 21.90 28 7330 10853 34938720
C-reactive protein abnormal 42.19 21.90 25 7333 8685 34940888
Diabetes mellitus 39.50 21.90 49 7309 46824 34902749
Pityriasis rubra pilaris 38.72 21.90 8 7350 103 34949470
Localised infection 38.63 21.90 31 7327 17556 34932017
Myalgia 36.10 21.90 64 7294 84046 34865527
Hyperkeratosis 36.00 21.90 17 7341 3732 34945841
Hypertension 35.08 21.90 84 7274 136359 34813214
Pain in extremity 34.83 21.90 80 7278 126433 34823140
Arthropathy 34.47 21.90 35 7323 26872 34922701
Malignant melanoma stage I 33.89 21.90 7 7351 90 34949483
Basal cell carcinoma 33.62 21.90 30 7328 19628 34929945
Botryomycosis 33.43 21.90 6 7352 34 34949539
Induration 33.01 21.90 11 7347 964 34948609
Neuroendocrine tumour of the lung metastatic 32.70 21.90 7 7351 108 34949465
Skin exfoliation 32.11 21.90 34 7324 27398 34922175
Toxicity to various agents 31.35 21.90 3 7355 200359 34749214
Synovitis 31.33 21.90 25 7333 14041 34935532
Decreased immune responsiveness 30.77 21.90 12 7346 1652 34947921
Acute kidney injury 30.62 21.90 13 7345 304975 34644598
Emotional distress 29.88 21.90 25 7333 15001 34934572
Muscular weakness 29.39 21.90 54 7304 72843 34876730
Retinal disorder 29.05 21.90 10 7348 967 34948606
Musculoskeletal stiffness 28.91 21.90 42 7316 46638 34902935
Therapeutic product effect decreased 28.75 21.90 36 7322 34707 34914866
Macule 28.26 21.90 11 7347 1506 34948067
Transaminases increased 27.48 21.90 31 7327 26792 34922781
Hepatic steatosis 27.46 21.90 26 7332 18336 34931237
Drug-induced liver injury 25.67 21.90 31 7327 28801 34920772
Diffuse idiopathic skeletal hyperostosis 25.63 21.90 5 7353 47 34949526
Joint swelling 24.94 21.90 45 7313 59845 34889728
Hidradenitis 24.32 21.90 9 7349 1073 34948500
Death 23.17 21.90 30 7328 398019 34551554
Gastrointestinal tube insertion 23.14 21.90 9 7349 1230 34948343
Hypereosinophilic syndrome 22.69 21.90 6 7352 235 34949338
Insomnia 22.52 21.90 60 7298 103847 34845726
Sticky skin 22.40 21.90 3 7355 0 34949573
Erythema 22.07 21.90 54 7304 88726 34860847

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 1427.73 18.89 573 15732 89014 79639069
Skin haemorrhage 251.56 18.89 94 16211 11887 79716196
Drug ineffective 226.79 18.89 602 15703 1080311 78647772
Skin exfoliation 189.90 18.89 126 16179 54974 79673109
Neurologic neglect syndrome 172.28 18.89 50 16255 2857 79725226
Skin plaque 171.18 18.89 69 16236 10676 79717407
Carotid artery thrombosis 169.86 18.89 50 16255 3003 79725080
Psoriatic arthropathy 163.34 18.89 132 16173 77867 79650216
Vein rupture 147.65 18.89 41 16264 1995 79726088
Personality disorder 135.51 18.89 50 16255 6096 79721987
Respiratory tract congestion 127.52 18.89 68 16237 19886 79708197
Adjustment disorder 124.30 18.89 42 16263 3958 79724125
Cutaneous T-cell lymphoma 119.14 18.89 37 16268 2666 79725417
Sneezing 117.19 18.89 64 16241 19619 79708464
Sinus congestion 116.54 18.89 64 16241 19832 79708251
Sinus disorder 111.94 18.89 65 16240 22399 79705684
Affect lability 109.37 18.89 51 16254 11208 79716875
Sensory loss 105.40 18.89 52 16253 12939 79715144
Squamous cell carcinoma 104.81 18.89 55 16250 15567 79712516
Erythrodermic psoriasis 98.71 18.89 29 16276 1729 79726354
Dermatitis exfoliative generalised 96.70 18.89 41 16264 7200 79720883
Motor dysfunction 96.37 18.89 51 16254 14682 79713401
Pruritus 95.48 18.89 233 16072 394415 79333668
Injection site haemorrhage 94.18 18.89 63 16242 27807 79700276
Hemiplegia 92.89 18.89 50 16255 14889 79713194
Coordination abnormal 86.01 18.89 50 16255 17262 79710821
Venous injury 85.96 18.89 22 16283 780 79727303
Pain of skin 85.56 18.89 47 16258 14566 79713517
Muscle spasticity 78.52 18.89 51 16254 21424 79706659
Rhinorrhoea 78.49 18.89 87 16218 75987 79652096
Joint ankylosis 76.14 18.89 25 16280 2155 79725928
Skin lesion 75.46 18.89 65 16240 41779 79686304
Toxicity to various agents 70.12 18.89 4 16301 421536 79306547
Inappropriate schedule of product administration 69.35 18.89 109 16196 133519 79594564
Keratoacanthoma 66.49 18.89 19 16286 1026 79727057
Eating disorder 65.66 18.89 45 16260 20652 79707431
Skin injury 65.23 18.89 25 16280 3381 79724702
Bone cyst 65.04 18.89 25 16280 3408 79724675
Injection site papule 63.95 18.89 18 16287 920 79727163
Cystitis 62.65 18.89 65 16240 52667 79675416
Therapeutic product effect incomplete 59.38 18.89 105 16200 141540 79586543
Osteolysis 58.50 18.89 25 16280 4473 79723610
Influenza 58.14 18.89 99 16206 129507 79598576
Hemiparesis 57.99 18.89 51 16254 33682 79694401
Aphasia 54.43 18.89 57 16248 46675 79681408
Squamous cell carcinoma of skin 52.96 18.89 34 16271 13999 79714084
Erythema 50.86 18.89 129 16176 223161 79504922
Rhesus antigen positive 49.03 18.89 10 16295 124 79727959
Muscular weakness 48.83 18.89 104 16201 160625 79567458
Oral lichen planus 48.02 18.89 14 16291 812 79727271
Hepatic fibrosis 47.03 18.89 25 16280 7255 79720828
Arterial occlusive disease 46.22 18.89 26 16279 8430 79719653
Influenza like illness 45.05 18.89 64 16241 71643 79656440
Gangrene 44.81 18.89 26 16279 8938 79719145
Pityriasis rubra pilaris 44.17 18.89 9 16296 111 79727972
Induration 43.46 18.89 16 16289 1936 79726147
Skin erosion 42.75 18.89 20 16285 4425 79723658
Hyperkeratosis 42.71 18.89 24 16281 7766 79720317
Alanine aminotransferase abnormal 42.43 18.89 25 16280 8842 79719241
Acute kidney injury 42.42 18.89 27 16278 519377 79208706
Onychalgia 41.82 18.89 13 16292 939 79727144
Phototherapy 41.21 18.89 7 16298 28 79728055
Rebound psoriasis 39.46 18.89 9 16296 194 79727889
Pustular psoriasis 38.27 18.89 19 16286 4787 79723296
Granuloma annulare 37.81 18.89 11 16294 633 79727450
Guttate psoriasis 36.61 18.89 10 16295 457 79727626
Gastrointestinal infection 36.54 18.89 25 16280 11436 79716647
Hepatic cirrhosis 36.11 18.89 40 16265 34866 79693217
Arthritis 35.64 18.89 75 16230 114805 79613278
Cataract 35.47 18.89 53 16252 62067 79666016
Dysphagia 34.76 18.89 77 16228 122059 79606024
Rash pustular 34.48 18.89 24 16281 11287 79716796
Hypotension 34.43 18.89 24 16281 440293 79287790
Infected dermal cyst 34.37 18.89 12 16293 1246 79726837
Dyslipidaemia 33.87 18.89 24 16281 11609 79716474
Skin fissures 33.58 18.89 25 16280 13048 79715035
Skin disorder 33.58 18.89 38 16267 33905 79694178
Sticky skin 33.10 18.89 5 16300 7 79728076
Neuroendocrine tumour of the lung metastatic 32.84 18.89 7 16298 109 79727974
Death 32.42 18.89 41 16264 566473 79161610
Lichen planus 31.38 18.89 14 16291 2777 79725306
Anaemia 31.31 18.89 27 16278 444988 79283095
Neutropenia 31.18 18.89 10 16295 287700 79440383
Injection site swelling 30.98 18.89 43 16262 47089 79680994
Malignant melanoma stage I 30.91 18.89 7 16298 146 79727937
Localised infection 30.46 18.89 38 16267 37537 79690546
Nasopharyngitis 30.12 18.89 117 16188 253764 79474319
Skin atrophy 29.69 18.89 17 16288 5701 79722382
Dysarthria 29.44 18.89 51 16254 67571 79660512
Dry skin 29.23 18.89 51 16254 67944 79660139
Immunoglobulins decreased 28.27 18.89 11 16294 1549 79726534
Weaning failure 28.23 18.89 9 16296 706 79727377
Dizziness 28.18 18.89 40 16265 526401 79201682
Type IIb hyperlipidaemia 27.75 18.89 5 16300 30 79728053
Pain in extremity 27.53 18.89 147 16158 364391 79363692
Myalgia 27.50 18.89 92 16213 185549 79542534
Macule 27.50 18.89 13 16292 2944 79725139
Infusion related reaction 26.78 18.89 7 16298 230230 79497853
Psoriasis area severity index increased 26.78 18.89 6 16299 119 79727964
Bone erosion 26.77 18.89 25 16280 17822 79710261
Hypercholesterolaemia 26.58 18.89 28 16277 23067 79705016
Wrong technique in device usage process 26.49 18.89 14 16291 4014 79724069
Blood immunoglobulin M decreased 26.48 18.89 10 16295 1299 79726784
Somnolence 26.44 18.89 8 16297 238973 79489110
Tongue ulceration 25.97 18.89 14 16291 4179 79723904
Diffuse alopecia 25.51 18.89 9 16296 964 79727119
Oesophageal stenosis 25.47 18.89 14 16291 4340 79723743
Blood albumin increased 25.19 18.89 10 16295 1485 79726598
Diffuse idiopathic skeletal hyperostosis 25.15 18.89 5 16300 54 79728029
Cerebrovascular accident 24.83 18.89 79 16226 155213 79572870
Botryomycosis 24.74 18.89 5 16300 59 79728024
Dehydration 24.55 18.89 10 16295 248177 79479906
Gastric disorder 24.38 18.89 34 16271 37399 79690684
Angina pectoris 23.81 18.89 40 16265 51692 79676391
Decreased appetite 23.80 18.89 21 16284 342397 79385686
Hyponatraemia 23.57 18.89 4 16301 177844 79550239
Red blood cell sedimentation rate abnormal 23.39 18.89 25 16280 20938 79707145
Tanning 23.16 18.89 5 16300 83 79728000
Dyspnoea 22.89 18.89 94 16211 856931 78871152
Constipation 22.68 18.89 15 16290 283035 79445048
Platelet count decreased 22.48 18.89 6 16299 194658 79533425
Blood pressure increased 22.34 18.89 94 16211 211266 79516817
Tremor 22.16 18.89 4 16301 170079 79558004
Cutaneous symptom 22.13 18.89 7 16298 535 79727548
Inflammatory bowel disease 22.09 18.89 14 16291 5637 79722446
Palmoplantar pustulosis 21.63 18.89 7 16298 576 79727507
Seizure 21.47 18.89 6 16299 188828 79539255
Thrombocytopenia 21.33 18.89 14 16291 265245 79462838
Cellulitis 20.75 18.89 59 16246 109001 79619082
Tonsil cancer 20.33 18.89 8 16297 1160 79726923
Burning sensation 20.21 18.89 40 16265 58592 79669491
Contraindicated product administered 19.89 18.89 4 16301 157534 79570549
Rash 19.77 18.89 57 16248 578301 79149782
Pain 19.67 18.89 225 16080 703577 79024506
Oesophageal ulcer 19.41 18.89 14 16291 6961 79721122
Injection site bruising 19.26 18.89 32 16273 40970 79687113
Intertrigo 19.19 18.89 7 16298 825 79727258
Skin infection 19.03 18.89 21 16284 18224 79709859

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D05BB02 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR SYSTEMIC USE
Retinoids for treatment of psoriasis
FDA CS M0018962 Retinoids
FDA EPC N0000175607 Retinoid
CHEBI has role CHEBI:50176 keratolytic drugs
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Severe Recalcitrant Psoriasis indication
Lichen planus off-label use 4776004 DOID:9201
Keratosis follicularis off-label use 48611009 DOID:2734
Lamellar ichthyosis off-label use 205550003
Ichthyosiform erythroderma off-label use 268282005
Primary cutaneous T-cell lymphoma off-label use 400122007
Alcoholism contraindication 7200002
Hypercholesterolemia contraindication 13644009
Depressive disorder contraindication 35489007
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Night blindness contraindication 65194006 DOID:8499
Benign intracranial hypertension contraindication 68267002 DOID:11459
Diabetes mellitus contraindication 73211009 DOID:9351
Premature epiphyseal closure contraindication 89493005
Liver function tests abnormal contraindication 166603001
Hypoalphalipoproteinemia contraindication 190785000
Acute pancreatitis contraindication 197456007 DOID:2913
Hypertrophy of bone contraindication 203514008 DOID:205
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Psychiatric Disturbance contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.17 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Retinoic acid receptor alpha Nuclear hormone receptor AGONIST WOMBAT-PK CHEMBL
Retinoic acid receptor gamma Nuclear hormone receptor AGONIST CHEMBL CHEMBL
Bile salt export pump Transporter IC50 4.74 CHEMBL
Bile salt export pump Transporter IC50 4.71 CHEMBL

External reference:

IDSource
4021061 VUID
N0000148524 NUI
D02754 KEGG_DRUG
16818 RXNORM
C0050559 UMLSCUI
CHEBI:50173 CHEBI
CHEMBL1131 ChEMBL_ID
DB00459 DRUGBANK_ID
D017255 MESH_DESCRIPTOR_UI
5284513 PUBCHEM_CID
7598 IUPHAR_LIGAND_ID
5530 INN_ID
69427-46-9 SECONDARY_CAS_RN
LCH760E9T7 UNII
108914001 SNOMEDCT_US
386938006 SNOMEDCT_US
4021061 VANDF
11379 MMSL
117161 MMSL
4128 MMSL
d03836 MMSL
004121 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1135 CAPSULE 10 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1135 CAPSULE 10 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1135 CAPSULE 10 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1136 CAPSULE 25 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1136 CAPSULE 25 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1136 CAPSULE 25 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1138 CAPSULE 17.50 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1138 CAPSULE 17.50 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1138 CAPSULE 17.50 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1750 CAPSULE 10 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1750 CAPSULE 10 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1751 CAPSULE 17.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1751 CAPSULE 17.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1752 CAPSULE 22.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1752 CAPSULE 22.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1753 CAPSULE 25 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1753 CAPSULE 25 mg ORAL ANDA 17 sections
SORIATANE HUMAN PRESCRIPTION DRUG LABEL 1 0145-0090 CAPSULE 10 mg ORAL NDA 27 sections
SORIATANE HUMAN PRESCRIPTION DRUG LABEL 1 0145-0091 CAPSULE 25 mg ORAL NDA 27 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7020 CAPSULE 10 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7020 CAPSULE 10 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7020 CAPSULE 10 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7023 CAPSULE 25 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7023 CAPSULE 25 mg ORAL ANDA 28 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7023 CAPSULE 25 mg ORAL ANDA 28 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-086 CAPSULE 10 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-087 CAPSULE 17.50 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-088 CAPSULE 25 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-080 CAPSULE 10 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-080 CAPSULE 10 mg ORAL ANDA 25 sections